Merck Immunotherapy Drug Shines In Lung Cancer Study
Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later, compared with about half of people who only got chemotherapy.
There's encouraging news for cancer treatments that stimulate the immune system to attack cancer cells. A widely used immunotherapy drug appears to be useful in a greater number of patients with lung cancer.
The drug called Keytruda, or pembrolizumab, is already prescribed to a group of patients who have a type of malignancy called non-small cell lung cancer. It's the principal form of lung cancer and found most commonly in people
